Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4729 in Healthy Subjects
NCT06762600Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-4729 in obesity (4 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Adverse events. Started Jan 2025; status: completed.
02
Drugs
HRS-4729
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06762600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762600.